Artivion Earnings Call Balances Growth With Caution

Artivion Inc. ((AORT)) has held its Q1 earnings call. Read on for the main highlights of the call.

Artivion’s latest earnings call struck a cautiously optimistic tone, blending solid double-digit revenue growth, expanding margins and rapid deleveraging with frank acknowledgment of near-term headwinds. Management emphasized strong product performance and a strategically important acquisition that deepens its aortic arch franchise, even as slower AMDS starter-set uptake and regional softness forced a guidance reset.

Robust Top-Line Growth in the Quarter

Artivion reported Q1 2026 revenues of $116.3 million, up 12% year over year on a constant currency basis and underscoring resilient demand across its cardiac and vascular portfolio. The performance showed that core procedures remain healthy despite localized pressures, positioning the company for continued expansion off a higher revenue base.

EBITDA Strength and Margin Expansion

Adjusted EBITDA climbed roughly 26% to $22.1 million, lifting the adjusted margin to 19% and marking about 130 basis points of year-over-year improvement. Management highlighted ongoing operating leverage and disciplined expense control as key drivers, signaling confidence in its ability to convert revenue growth into steadily improving profitability.

Product Lines Drive Performance

The On-X mechanical valve franchise delivered standout 17% constant-currency growth, while tissue processing surged 23% as volumes normalized after last year’s cybersecurity disruption. Stent graft revenue increased 10% and BioGlue was essentially flat, with management framing the latter as normal distributor stocking variability but still slightly below internal growth expectations.

AMDS Usage Encouraging Despite Starter-Set Lag

Within accounts that have adopted AMDS, implant and reorder trends were stronger than expected, reinforcing management’s belief in the product’s long-term role in aortic repair. The main drag was slower U.S. starter-set sales, which carry a significant upfront price tag and were delayed by administrative processes and hospitals waiting for full approval.

Aortic Arch Portfolio Enhanced by Endospan Deal

Artivion exercised its option to acquire Endospan following approval of the NEXUS system, rounding out a three-pronged aortic arch platform alongside AMDS and the future C-Branch LSA. Management is targeting a U.S. launch of NEXUS at the start of 2027 and sees a sizable domestic opportunity, with dissections representing the majority of the potential market.

Pipeline Advances Underpin Long-Term Growth

The ARTISON IDE trial for the next-generation frozen elephant trunk device has enrolled 26 of 132 planned patients, with full enrollment expected by mid-2027, pointing to a multi-year innovation runway. C-Branch LSA is anticipated to secure approval near the end of the decade, opening an additional market niche and reinforcing Artivion’s strategy in complex aortic work.

Balance Sheet Strengthens as Leverage Falls

Net leverage improved sharply to 1.8 times at the end of March from 4.0 times a year earlier, supported by improved earnings and better cash discipline. Free cash flow remained negative at $6.8 million in what is seasonally a weaker quarter but showed meaningful improvement versus the prior-year outflow, giving the company more financial flexibility.

Guidance Trim Reflects Moderated Growth Outlook

Management reduced its 2026 adjusted constant-currency revenue growth outlook to a 7%–11% range, corresponding to reported sales of $480 million to $496 million. The reset reflects Q1 shortfalls and embedded conservatism around stent graft softness and AMDS starter-set timing, balancing near-term caution with still-healthy mid- to high-single-digit to low-teens growth expectations.

AMDS Starter-Set Timing a Key Near-Term Drag

Lower-than-expected U.S. sales of AMDS starter sets, which are bundled four-unit purchases around $100,000, played a significant role in the guidance reduction. Hospitals’ internal review processes and the decision by some to wait for full approval pushed these high-ticket orders into later periods, but management stressed that underlying usage trends remain supportive.

International Markets Hit by Regional Volatility

International results lagged the company’s usual performance patterns, with EMEA growing 5%, Asia Pacific 6% and Latin America down 23%. Softness in the Middle East and uneven distributor ordering notably weighed on stent grafts and overall ex-U.S. sales, underscoring the impact of regional macro and channel dynamics on quarterly volatility.

Targeted Supply Chain Constraints Weigh on Stent Grafts

Supply chain bottlenecks affecting certain stent graft SKUs contributed to the softer-than-hoped 10% constant-currency growth in that segment. Management outlined remediation efforts but admitted that the timeline for full normalization remains uncertain, a factor already incorporated into the updated outlook.

Endospan Deal to Pressure Near-Term Earnings

Funding the Endospan acquisition via a $150 million loan will introduce roughly $8 million of additional expense through 2026 tied to integration and launch preparation. As a result, adjusted EBITDA guidance excluding the transaction will step down once the deal closes, reflecting management’s choice to absorb near-term P&L pressure in pursuit of a broader aortic arch franchise.

Cash Flow Improves as Interest Costs Set to Rise

The company’s free cash flow loss narrowed materially year over year, reflecting better underlying profitability and working-capital management. However, interest expense, which was $5.2 million in the quarter, is expected to climb in the back half of 2026 as the new term loan draws push quarterly interest payments higher.

Updated Outlook and Forward-Looking Guidance

Artivion now projects full-year revenue of $480 million to $496 million with currency providing a modest tailwind and adjusted EBITDA of $100 million to $107 million before factoring in Endospan-related costs. The guidance assumes minimal domestic NEXUS contribution this year, approval milestones for AMDS, softness in certain product lines and higher interest expense, but still anticipates margin expansion as scale benefits build.

Artivion’s earnings call painted a picture of a company balancing strong underlying momentum with realistic near-term caution. For investors, the story hinges on management’s ability to resolve AMDS and supply-chain bottlenecks while integrating Endospan, with a robust innovation pipeline and improving balance sheet offering meaningful upside over the longer term.